Summit Moving Lead Drugs with Wellcome Trust Award

LONDON – Summit plc is making headway with its two lead programs, winning a £4 million (US$6.42 million) translation award from the Wellcome Trust for clinical trials of SMT19969, a narrow-spectrum antibiotic for treating Clostridium difficile infections, and starting Phase II development of SMT-C1100, a treatment for Duchenne's muscular dystrophy (DMD).